PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis

Por Anink, J, Otten, MH, Van Suijlekom-Smit, LA, Van Rossum, MA, Dolman, KM, Hoppenreijs, EP, Ten Cate, R, Vogl, T, Foell, D, Roth, J, Holzinger, D
Publicado em 2013

Etanercept in juvenile idiopathic arthritis: Who will benefit?

Por van den Berg JM, Swart JF, Dolman KM, Gorter SL, Koopman-Keemink Y, Twilt M, Hoppenreijs EPAH, ten Cate R, Armbrust W, Prince FHM, Otten MH, Wulffraat NM, van Rossum MAJ, van Suijlekom-Smit LWA
Publicado em 2011-09-01

Etanercept in juvenile idiopathic arthritis: Who will benefit?

Por Otten, MH, Prince, FHM, Armbrust, W, ten Cate, R, Hoppenreijs, EPAH, Twilt, M, Koopman-Keemink, Y, Gorter, SL, Dolman, KM, Swart, JF, van den Berg, JM, Wulffraat, NM, van Rossum, MAJ, van Suijlekom-Smit, LWA
Publicado em 2011

PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register

Por Otten, MH, Anink, J, Prince, FH, Twilt, M, Vastert, SJ, Ten Cate, R, Hoppenreijs, EP, Armbrust, W, Gorter, SL, Van Pelt, PA, Kamphuis, S, Dolman, KM, Swart, JF, Van den Berg, JM, Koopman-Keemink, Y, Van Rossum, MA, Wulffraat, NM, Van Suijlekom-Smit, LA
Publicado em 2013